Table 2.
Tumour characteristics at baseline—PP population
| Trabectedin N = 115 |
|
|---|---|
| Status of disease at study entry, n (%) | |
| Progression | 79 (68.7) |
| Recurrence | 33 (28.7) |
| Persistent | 3 (2.6) |
| Site of disease at study entry, n (%) | |
| Only pelvic | 8 (7.0) |
| Only distant metastasis | 71 (61.7) |
| 1 site of metastasis | 35 (49.3) |
| 2 sites of metastasis | 22 (31.0) |
| 3 sites of metastasis | 9 (12.7) |
| >3 sites of metastasis | 5 (7.0) |
| Pelvic plus distant metastasis | 36 (31.3) |
| 1 site of metastasis | 16 (44.4) |
| 2 sites of metastasis | 11 (30.6) |
| 3 sites of metastasis | 6 (16.7) |
| >3 sites of metastasis | 3 (8.3) |
| Peritoneum, n (%) | 39 (33.9) |
| Liver, n (%) | 18 (15.7) |
| Spleen, n (%) | 4 (3.5) |
| Lung, n (%) | 75 (65.2) |
| Bone, n (%) | 18 (15.7) |
| Intra-abdominal lymph nodes, n (%) | 10 (8.7) |
| Extra-abdominal lymph nodes, n (%) | 9 (7.8) |
| Abdominal wall, n (%) | 5 (4.3) |
| Other, n (%) | 19 (16.5) |